Flatiron Health

Flatiron Health

HQ
New York
Total Offices: 5
2,500 Total Employees
Year Founded: 2012

Flatiron Health Company Growth, Stability & Outlook

Updated on October 26, 2026

Frequently Asked Questions

Financial Health

Flatiron Health’s stability is reflected in the way its oncology technology platform supports long-term needs in cancer care. The company sits at the center of work that helps oncology practices, researchers and life sciences organizations use real-world data to improve care and clinical research, giving its business a durable role in the healthcare ecosystem. 

  • A durable role in oncology infrastructure: Flatiron’s business is anchored in cancer care infrastructure through its oncology-specific EHR and real-world data work. An associate principal of clinical research partnerships said Flatiron has “pioneered the oncology real-world evidence industry” and reimagined community oncology infrastructure through OncoEMR. That role suggests stability because Flatiron’s work is tied to ongoing healthcare needs, not short-term product demand. 
  • Growth in life sciences and research: Flatiron’s Research Triangle Life Sciences Hub points to continued investment in talent and customer work within a major life sciences region. An associate principal of clinical research partnerships said the area’s biotech and CRO ecosystem makes it an ideal place for Flatiron to keep growing its life sciences business. A head of research oncology also described Flatiron’s clinical research work as helping sponsors and research sites make cancer trials more accessible, efficient and representative. 
  • Ongoing investment in people and capability: Flatiron’s employee experience suggests a company still investing in the systems needed to retain talent and operate over time. Its benefits include comprehensive compensation, retirement support and financial advisement, while its development model gives employees access to manager training and Flatiron University. The company’s hybrid work approach and office investments also point to a workplace model built for sustained operations. 
  • External signals:
    • What employees cite as strengths: External reviews highlight meaningful oncology work, flexibility, supportive management and a clear sense of purpose. Those themes matter for stability because employees often connect confidence in an employer to mission clarity and the ability to do durable, well-supported work. (Indeed, Glassdoor)
    • Confidence in direction: External reviews describe positive direction under newer CEO and COO leadership, a strong scientific culture and meaningful oncology technology impact. Comparably data also notes employee satisfaction with outlook, retention, team and CEO rating. (Glassdoor, Comparably)

Bottom line: Flatiron Health’s clearest stability indicators come from its established role in oncology infrastructure, continued investment in life sciences growth and employee feedback that points to confidence in the company’s mission and direction. 

Flatiron Health's Candidate Tradeoffs

If you’re weighing whether Flatiron Health is the right fit, these are the core tradeoffs to consider.

  • Flatiron Health places greater emphasis on organizational adaptability and evolving opportunity than on clearly defined roles and highly stable team structures.

Flatiron Health Employee Perspectives

Flatiron’s growth in the Research Triangle reflects long-term stability, rooted in a region with decades of life sciences expertise, strong talent, and continued room for expansion.

“The Research Triangle has been a hub for biotech and the CRO industry for decades now. The rich history and culture of life sciences innovation, access to talented individuals for expansion, and the growth potential of the area in general make it an ideal location for Flatiron to continue growing our life sciences business. It's an exciting time to be at Flatiron as we build a local presence here.”

Nathan Hobrath
Nathan Hobrath, Associate Principal of Clinical Research Partnerships

What People Are Saying About Flatiron Health

  • Strong Revenue Growth: Revenue is reported to have nearly doubled during CEO Carolyn Starrett’s tenure beginning in 2021, alongside expansion of the real‑world data platform and commercial evidence services. This is the clearest direct indicator of commercial momentum even though underlying figures were not disclosed.
  • Market Expansion: International oncology research reach expanded markedly, with the network tripling in 2025 and then growing nearly 70% year over year by July 2026 to more than 50 sites across the UK, Germany and Japan, including a first partnership in Scotland. This points to broader geographic access and commercial reach.
  • Product Line Growth: Data assets and offerings have broadened, with the evidence base growing to more than six million patient records and launches such as the AI-enabled Telescope platform and expanded Panoramic datasets. These developments indicate deeper research utility and a wider product portfolio.